IVD China last week: Mindray, YHLO, Lifotronic, Wondfo and MedAccess

Lifotronic Reports 2024 Half-Year Net Income of RMB 172 Million, Up 27.78% Year-on-Year

Lifotronic announced its 2024 half-year results on August 27, reporting an operating revenue of approximately RMB 590 million, a 5.64% increase year-on-year. The net profit attributable to shareholders reached around RMB 172 million, reflecting a 27.78% year-on-year growth, with basic earnings per share (EPS) rising by 25% to RMB 0.4.

Additional highlights include:

1. Over the past 30 days, northbound fund holdings in Lifotronic Technology increased by 645,400 shares, representing a 0.16% rise in outstanding shares.

2. In the same period, 97 research institutions participated in one round of institutional research on the Pu Gate Science and Technology platform.

Wondfo Partners with MedAccess to Advance Global Public Health

On August 26, Wondfo hosted a visit from Michelle Tao, Director of Public Health Investment and Development, and Evans Mburu, Executive Director of MedAccess, an international non-profit organization. The delegation was warmly welcomed by Wondfo teams.

During the visit, MedAccess praised the ongoing collaboration between the two organizations, particularly their joint efforts in developing HIV self-testing products. The discussion also focused on deepening future cooperation and expanding their partnership to include malaria testing. Both parties explored strategies to promote the malaria product that recently received World Health Organization PQ certification in July, aiming to enhance global malaria prevention and treatment efforts.